Overview

Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement

Status:
Terminated
Trial end date:
2018-11-13
Target enrollment:
Participant gender:
Summary
This is a phase 2 study to see how effective investigational drug, JNJ-42756493, is when given in combination with dexamethasone in two groups of patients with multiple myeloma (cancer of the plasma cells, a type of white blood cell present in bone marrow) that has relapsed (has come back after a period of improvement) or refractory (did not respond to standard treatment).
Phase:
Phase 2
Details
Lead Sponsor:
University Health Network, Toronto
Collaborator:
Multiple Myeloma Research Consortium
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate